Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, PeptiDream and Pfizer.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Nov 7, 2018
Sosei enters collaboration to combine pioneering DNA technologies with StaR® technology to accelerate new drug discovery
Nov 1, 2018
Chris Cargill appointed Executive Vice President and Chief Financial Officer of Sosei
© 2012-2018 Heptares Therapeutics